GlassScriptPhysician profile
Peter Robert Triporo
NPI 1184050544
$15,190.84
in general payments reported to CMS, 2019-2025
36 companies · $3,586 in 2025
The $3,586 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,556 · 2022: $4,325 · 2023: $2,801 · 2024: $2,923 · 2025: $3,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,288 · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,288.37 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $7,148.94 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,302.38 | 2021-2025 | Biktarvy, Descovy |
| Merck Sharp & Dohme LLC | $1,222.57 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $699.61 | 2021-2025 | |
| Emd Serono, INC. | $515.31 | 2021-2025 | Serostim |
| Janssen Biotech, INC. | $484.80 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $313.42 | 2021-2025 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $308.36 | 2022-2025 | Mytesi |
| Novo Nordisk INC | $301.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.65 | 2023-2025 | Caplyta |
| Antares Pharma, INC. | $165.00 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Otsuka America Pharmaceutical, INC. | $163.43 | 2024-2025 | Rexulti |
| Acacia Pharma INC | $135.33 | 2021 | |
| Janssen Products, LP | $134.95 | 2021-2022 | |
| Pfizer INC. | $128.39 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.88 | 2022-2025 | Zepbound, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $88.91 | 2021-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $78.27 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $72.91 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $71.17 | 2024 | Qelbree, Xyosted |
| Janssen Pharmaceuticals, INC | $67.69 | 2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $60.97 | 2023-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $50.52 | 2021 | |
| Abbott Laboratories | $43.39 | 2021-2025 | Freestyle Libre 3 |
| Alkermes, INC. | $35.71 | 2023-2024 | Vivitrol, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.37 | 2021-2023 | Xifaxan |
| Verity Pharmaceuticals INC. | $33.85 | 2024-2025 | Tlando |
| Amgen INC. | $32.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.42 | 2021-2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $27.28 | 2022 | |
| Allergan, INC. | $22.45 | 2022 | |
| Tolmar, INC. | $19.06 | 2025 | Jatenzo |
| Eisai INC. | $16.16 | 2021 | |
| Orexo US, INC. | $14.49 | 2025 | Zubsolv |
| Acerus Pharmaceuticals Corporation | $13.16 | 2022 | |
| Halozyme INC | $12.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Triporo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.